Skip to main content
RMDResMed Inc.Buy Wait5.7·$229.20-0.72%

ResMed (RMD) Q2 2026 earnings — TrendMatrix coverage

BEAT+2.0% vs estimateEPS $2.95 vs $2.89 estCurrent verdict Buy (Wait) 5.7/10

Reported

Model-generated analysis — not investment advice. Not a registered investment advisor. Past performance does not guarantee future results. How we score · Full disclosure

Event detail · Q2 2026

Key numbers

Reported EPS
$2.95
Estimate
$2.89
Surprise
+2.0%
Score today
5.7/10

Revenue for this quarter isn’t shown: the reported figure hasn’t cleared TrendMatrix’s freshness and sanity checks yet, and consensus revenue isn’t tracked. EPS above is the available figure.

Report record · Q2 2026

How the report landed

ResMed (RMD) beat the $2.89 estimate with diluted EPS of $2.95 — a modest 2.0% upside surprise.

Current read · as of 2026-09-04

Where TrendMatrix's rating stands now

TrendMatrix currently rates RMD Buy (Wait) at 5.7/10; no pre/post engine snapshot brackets this report.

4 of the last 4 quarters beat the estimate; this quarter's +2.0% surprise compares with a +2.3% four-quarter average. Next scheduled report: 2026-10-29.

What supports the rating

  • V7 flight-to-quality bonus: +0.5 (Q=8.8 in RISK_OFF)
  • Sector modifier (Healthcare): +0.5

What argues against it

  • Concentration risk — Geographic: manufacturing outside the U.S.
  • Analyst target reached - limited upside remaining
  • Weak growth

This section and the ones below it reflect TrendMatrix’s latest engine read — they update after the report date and are not frozen to it.

Current engine read

The levels TrendMatrix's engine tracks

Current price
$229.20
Entry target
$213.55
Price target
$237.55
Stop
$200.85
Upside to target
+3.6%

The stock trades at 22.2× trailing but 17.5× forward earnings — consensus estimates already build in a substantial earnings recovery.

Model outputs from TrendMatrix’s engine as of 2026-09-04 — shown for context, not personalized investment advice.

Healthcare context

RMD at TrendMatrix's latest read

Healthcare earnings trade on pipeline and payer dynamics as much as the quarter itself; a beat or miss is weighed against trial and reimbursement news.

Industry
Medical Instruments & Supplies
Market cap
$33.30B
P/E (fwd)
17.5
P/E (ttm)
22.2
52-week range
$180.27$284.87
Off 52-week high
19.5%
RSI (14)
56
Volume vs avg
0.98×
Score today
5.7/10

Earnings figures are sourced from TrendMatrix’s pipeline (EPS: existing earnings extraction; revenue: SEC XBRL company facts where available, yfinance-provisional otherwise). Not a buy/sell rating, a price target, or investment advice — see the current verdict on the stock’s main page for TrendMatrix’s live read.

Home Stocks RMD Earnings Q2 2026 earnings